A case of late-onset hepatic veno-occlusive disease after hematopoietic stem cell transplantation in which ultrasonography was useful for the diagnosis and follow-up

Kojima, Yoshiyuki; Maeoka, Etuko; Nisaka, Yoshimi; Fukushima, Y; Hashimoto, Takunori; Satou, Aya; Naitou, Miwa; Tadenuma, Misa; Morimoto, Hirotoshi; Yuasa, Norihiro

doi:10.3179/jjmu.jjmu.a.166

Cited by 1 publication

(1 citation statement)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The 197 patients in 2 comparative studies were adults [108] or mostly adults (median age 48 years, range 16-70 years) [109], as was one of the single cases reported [115]. The remaining studies and case reports of 326 patients were performed exclusively or mostly in children (age range < 1-18 years).…”

Section: Population Exposurementioning

confidence: 99%

Danaparoid Sodium: A Review of Its Use in Hepatic Thrombotic Disorders

Magnani¹

2022

Anticoagulation - Current Perspectives

View full text Add to dashboard Cite

Danaparoid sodium is an antithrombotic isolated from porcine mucosa. Its main constituent is a mixture of heparan sulphates that inhibits thrombin generation and also possesses anti-inflammatory and immune-modulatory activity. It has shown safety and efficacy in its main indications of deep venous thrombosis prophylaxis, heparin-induced thrombocytopenia treatment and disseminated intravascular thrombosis treatment. In addition, there are reports of its off-label use for the treatment of portal vein thrombosis in adults and for prevention of the hepatic thrombotic microangiopathies haematogenous that complicate recovery after stem cell transplantation in adults and children. The results of these studies provide further support for its safety and efficacy even in subjects with cirrhosis and/or severe hepatic dysfunction. In this chapter the rationale for danaparoid use is presented and the collated results of comparative studies and case reports are compared with those of other pharmaceutical options for managing these hepatic thrombotic disorders.

show abstract

Section: Population Exposurementioning

confidence: 99%

Danaparoid Sodium: A Review of Its Use in Hepatic Thrombotic Disorders

Magnani¹

2022

Anticoagulation - Current Perspectives

View full text Add to dashboard Cite

show abstract

A case of late-onset hepatic veno-occlusive disease after hematopoietic stem cell transplantation in which ultrasonography was useful for the diagnosis and follow-up

Cited by 1 publication

References 14 publications

Danaparoid Sodium: A Review of Its Use in Hepatic Thrombotic Disorders

Danaparoid Sodium: A Review of Its Use in Hepatic Thrombotic Disorders

Contact Info

Product

Resources

About